Caribou Biosciences (CRBU) Liabilities and Shareholders Equity (2020 - 2026)

Caribou Biosciences (CRBU) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $149.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 45.55% year-over-year to $149.0 million; the TTM figure through Mar 2026 stood at $740.3 million (down 43.24% YoY), while the FY2025 annual figure was $175.4 million, down 44.03% from the prior year.
• Liabilities and Shareholders Equity slipped to $149.0 million in Q1 2026 per CRBU's latest filing, from $175.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $457.5 million in Q3 2023 and bottomed at $149.0 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $334.0 million across 5 years, with a median of $349.6 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 166.02% — and 2026, when it slumped 45.55%.
• Caribou Biosciences' Liabilities and Shareholders Equity stood at $373.8 million in 2022, then grew by 15.64% to $432.2 million in 2023, then declined by 27.51% to $313.3 million in 2024, then plunged by 44.03% to $175.4 million in 2025, then decreased by 15.04% to $149.0 million in 2026.
• Business Quant data shows CRBU's Liabilities and Shareholders Equity at $149.0 million in Q1 2026, $175.4 million in Q4 2025, and $195.0 million in Q3 2025.